JP5399612B2 - Cnsを治療するための融合タンパク質 - Google Patents
Cnsを治療するための融合タンパク質 Download PDFInfo
- Publication number
- JP5399612B2 JP5399612B2 JP2006533212A JP2006533212A JP5399612B2 JP 5399612 B2 JP5399612 B2 JP 5399612B2 JP 2006533212 A JP2006533212 A JP 2006533212A JP 2006533212 A JP2006533212 A JP 2006533212A JP 5399612 B2 JP5399612 B2 JP 5399612B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chondroitinase
- protein
- tat
- abci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Description
本明細書は、2003年5月16日に提出された米国仮出願番号第60/471,239号(代理人整理番号127304.01200)、2003年5月16日に提出された米国仮出願番号第60/471,300号(代理人整理番号127304.01400)、2003年5月16日に提出された米国仮出願番号第60/474,372号(代理人整理番号127304.01700)、2003年5月16日に提出された米国仮出願番号第60/471,240号(代理人整理番号127304.01300)、及び2004年5月17日に本明細書と同時に提出された表題「CNS治療に対するプロテオグリカン分解変異体」の米国特許出願明細書(米国特許出願番号[未定]、代理人整理番号127304.01301)の利益と優先権を主張するものであり、これらの各引用文献の全体の内容は、この参考によって本明細書に組み込まれるものである。
この出願の発明に関連する先行技術文献情報としては次のものがある。
フランケル(Frankel)ら、ヒト免疫欠損ウイルスからのTatタンパク質による金属結合二量体の形成(Tat Protein from Human Immunodeficiency Virus Forms a Metal−Linked Dimer.)、サイエンス(Science)、1998年、240巻、p.70−73 ズオ(Zuo)ら、コンドロイチン硫酸プロテオグリカンの分解による神経切断修復後の軸索の再生促進(Regeneration of Axon after Nerve Transection Repair is Enhanced by Degredation of Chondroitin Sulfate Proteoglycan.)、神経学実験(Experimental Neurology)、2002年、176巻、p.221−228
本発明の実施形態の他の観点、特徴、利益、及び利点は、以下の説明、添付された請求項、及び添付された図面によって理解されるであろう。
Claims (6)
- 脊髄損傷後の神経機能の回復を促進するための組成物であって、融合ペプチドを有し、前記融合ペプチドは、タンパク質形質導入ドメイン及びコンドロイチナーゼABCIドメインを有し、前記コンドロイチナーゼABCIドメインはシグナル配列を有さないものである、組成物。
- 請求項1の組成物において、前記組成物は、CNS損傷の部位の近くに移植された、遺伝的に修飾された細胞によって分泌されるものである、組成物。
- 請求項1の組成物において、この組成物は、さらに、
前記タンパク質形質導入ドメインをコードするアミノ酸配列と、前記コンドロイチナーゼABCIドメインをコードするアミノ酸配列との間に、連結ポリペプチドを有するものである、組成物。 - 請求項1の組成物において、前記タンパク質形質導入ドメインはTATドメインである、組成物。
- 請求項1の組成物において、前記コンドロイチナーゼABCIドメインは、コンドロイチナーゼABCIの欠損変異体である、組成物。
- 請求項1の組成物において、前記融合ペプチドは、さらに、ニューロン再生を促進するドメインを有するものである、組成物。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47123603P | 2003-05-16 | 2003-05-16 | |
US47123903P | 2003-05-16 | 2003-05-16 | |
US47130003P | 2003-05-16 | 2003-05-16 | |
US60/471,236 | 2003-05-16 | ||
US60/471,300 | 2003-05-16 | ||
US60/471,239 | 2003-05-16 | ||
US47437203P | 2003-05-29 | 2003-05-29 | |
US60/474,372 | 2003-05-29 | ||
PCT/US2004/015661 WO2004110359A2 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for the treatment of cns |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012215041A Division JP5656314B2 (ja) | 2003-05-16 | 2012-09-27 | Cnsを治療するための融合タンパク質 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007516229A JP2007516229A (ja) | 2007-06-21 |
JP2007516229A5 JP2007516229A5 (ja) | 2007-08-02 |
JP5399612B2 true JP5399612B2 (ja) | 2014-01-29 |
Family
ID=33556640
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006533212A Expired - Fee Related JP5399612B2 (ja) | 2003-05-16 | 2004-05-17 | Cnsを治療するための融合タンパク質 |
JP2012215041A Expired - Fee Related JP5656314B2 (ja) | 2003-05-16 | 2012-09-27 | Cnsを治療するための融合タンパク質 |
JP2014138911A Expired - Fee Related JP6141571B2 (ja) | 2003-05-16 | 2014-07-04 | Cnsを治療するための融合タンパク質 |
JP2017030467A Expired - Lifetime JP6913428B2 (ja) | 2003-05-16 | 2017-02-21 | Cnsを治療するための融合タンパク質 |
JP2020034479A Pending JP2020111578A (ja) | 2003-05-16 | 2020-02-29 | Cnsを治療するための融合タンパク質 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012215041A Expired - Fee Related JP5656314B2 (ja) | 2003-05-16 | 2012-09-27 | Cnsを治療するための融合タンパク質 |
JP2014138911A Expired - Fee Related JP6141571B2 (ja) | 2003-05-16 | 2014-07-04 | Cnsを治療するための融合タンパク質 |
JP2017030467A Expired - Lifetime JP6913428B2 (ja) | 2003-05-16 | 2017-02-21 | Cnsを治療するための融合タンパク質 |
JP2020034479A Pending JP2020111578A (ja) | 2003-05-16 | 2020-02-29 | Cnsを治療するための融合タンパク質 |
Country Status (7)
Country | Link |
---|---|
EP (3) | EP3210999B1 (ja) |
JP (5) | JP5399612B2 (ja) |
AU (1) | AU2004247025B8 (ja) |
CA (1) | CA2525782C (ja) |
ES (1) | ES2831031T3 (ja) |
MX (2) | MXPA05012306A (ja) |
WO (1) | WO2004110359A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666852B2 (en) * | 2002-04-22 | 2010-02-23 | Agenta Biotechnologies, Inc. | Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide |
WO2004108069A2 (en) | 2002-05-04 | 2004-12-16 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
EP2460881B1 (en) | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of CNS |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
WO2005112986A2 (en) * | 2004-05-18 | 2005-12-01 | Acorda Therapeutics, Inc. | Purifying chondroitinase and stable formulations thereof |
JP5189985B2 (ja) | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク. | コンドロイチナーゼabci変異体を用いた組成物およびその使用方法 |
US8968728B2 (en) * | 2006-05-12 | 2015-03-03 | Bharat Biotech International Limited | Chimeric fusion proteins |
CN101489582B (zh) | 2006-05-19 | 2015-11-25 | 爱知县 | 脑损伤改善药 |
ES2473610T3 (es) * | 2006-10-10 | 2014-07-07 | Acorda Therapeutics, Inc. | Composiciones y métodos de uso de mutantes de condroitinasa ABCI |
ES2437110T3 (es) * | 2006-11-14 | 2014-01-08 | Genentech, Inc. | Moduladores de la regeneración neuronal |
WO2008149428A1 (ja) * | 2007-06-05 | 2008-12-11 | Glycoscience Laboratories, Inc. | 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤 |
AU2009217606B2 (en) | 2008-02-29 | 2015-03-05 | Acorda Therapeutics, Inc. | Method for achieving desired glial growth factor 2 plasma levels |
AU2015200220A1 (en) * | 2008-02-29 | 2015-02-12 | Acorda Therapeutics, Inc. | Method for achieving desired glial growth factor 2 plasma levels |
CA2845198A1 (en) * | 2010-08-13 | 2012-02-16 | Georgetown University | Ggf2 and methods of use |
EP2756849B1 (en) * | 2011-09-15 | 2016-03-16 | Seikagaku Corporation | Skeletal muscle regeneration promoter |
GB201322396D0 (en) | 2013-12-18 | 2014-02-05 | Univ Nottingham | Transduction |
US11396529B2 (en) | 2020-11-12 | 2022-07-26 | National Sun Yat-Sen University | Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
JPH09500011A (ja) * | 1993-04-23 | 1997-01-07 | アメリカン サイアナミド カンパニー | P.ブルガリスからのコンドロイチナーゼi及びii遺伝子のクローニング及び発現 |
AU1176595A (en) * | 1993-11-12 | 1995-05-29 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
JPH07316068A (ja) * | 1994-05-25 | 1995-12-05 | Canji Inc | 腫瘍サプレッサー融合タンパク質 |
GB9622500D0 (en) * | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
EP1157275A4 (en) * | 1999-02-28 | 2003-01-15 | Univ Washington | NEW TRANSDUCTION MOLECULES AND METHOD FOR USING THE SAME |
EP1161455B1 (en) * | 1999-03-16 | 2008-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A novel chimeric protein for prevention and treatment of hiv infection |
SE9901428D0 (sv) * | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
UA74146C2 (uk) * | 1999-06-08 | 2005-11-15 | Редженерон Фармасьютікалс, Інк. | Модифікований хімеричний поліпептид з покращеними фармакокінетичними властивостями |
JP2004504262A (ja) * | 1999-12-02 | 2004-02-12 | アイベックス テクノロジーズ, インコーポレイテッド | 線維芽細胞の増殖の弱毒化 |
US20020142299A1 (en) * | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
IL160188A0 (en) * | 2001-08-13 | 2004-07-25 | Univ Florida | Materials and methods to promote repair of nerve tissue |
GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
EP1521523A4 (en) * | 2002-05-20 | 2006-04-19 | Univ Texas | METHODS AND COMPOSITIONS FOR DELIVERING NUCLEIC ACID ENZYMES AND MOLECULES IN BRAIN, BONE, AND OTHER FABRICS |
US20060153827A1 (en) * | 2002-08-15 | 2006-07-13 | Gruskin Elliott A | Chimeric protein |
-
2004
- 2004-05-17 MX MXPA05012306A patent/MXPA05012306A/es active IP Right Grant
- 2004-05-17 CA CA2525782A patent/CA2525782C/en not_active Expired - Fee Related
- 2004-05-17 JP JP2006533212A patent/JP5399612B2/ja not_active Expired - Fee Related
- 2004-05-17 MX MX2012003710A patent/MX351062B/es unknown
- 2004-05-17 EP EP17164945.2A patent/EP3210999B1/en not_active Expired - Lifetime
- 2004-05-17 AU AU2004247025A patent/AU2004247025B8/en not_active Ceased
- 2004-05-17 EP EP10184697.0A patent/EP2354155B1/en not_active Expired - Lifetime
- 2004-05-17 EP EP04776038A patent/EP1646353A4/en not_active Ceased
- 2004-05-17 ES ES17164945T patent/ES2831031T3/es not_active Expired - Lifetime
- 2004-05-17 WO PCT/US2004/015661 patent/WO2004110359A2/en active Application Filing
-
2012
- 2012-09-27 JP JP2012215041A patent/JP5656314B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 JP JP2014138911A patent/JP6141571B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-21 JP JP2017030467A patent/JP6913428B2/ja not_active Expired - Lifetime
-
2020
- 2020-02-29 JP JP2020034479A patent/JP2020111578A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MXPA05012306A (es) | 2006-04-18 |
JP2013049677A (ja) | 2013-03-14 |
EP3210999A1 (en) | 2017-08-30 |
EP2354155B1 (en) | 2017-05-03 |
ES2831031T3 (es) | 2021-06-07 |
JP6913428B2 (ja) | 2021-08-04 |
MX351062B (es) | 2017-09-29 |
AU2004247025B8 (en) | 2011-06-30 |
WO2004110359A3 (en) | 2006-08-17 |
EP1646353A2 (en) | 2006-04-19 |
AU2004247025A1 (en) | 2004-12-23 |
JP2017125035A (ja) | 2017-07-20 |
EP2354155A3 (en) | 2011-09-07 |
EP3210999B1 (en) | 2020-08-26 |
EP2354155A2 (en) | 2011-08-10 |
JP2014221793A (ja) | 2014-11-27 |
CA2525782C (en) | 2019-02-05 |
JP2007516229A (ja) | 2007-06-21 |
JP5656314B2 (ja) | 2015-01-21 |
CA2525782A1 (en) | 2004-12-23 |
JP2020111578A (ja) | 2020-07-27 |
WO2004110359A9 (en) | 2006-02-16 |
EP1646353A4 (en) | 2008-06-04 |
AU2004247025B2 (en) | 2011-06-23 |
WO2004110359A2 (en) | 2004-12-23 |
JP6141571B2 (ja) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6913428B2 (ja) | Cnsを治療するための融合タンパク質 | |
US8906363B2 (en) | Fusion proteins for the treatment of CNS | |
JP2007516229A5 (ja) | ||
AU2014265113B2 (en) | Fusion proteins for the treatment of cns | |
ES2638819T3 (es) | Proteínas de fusión para el tratamiento del SNC |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070517 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120327 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120622 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120927 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130524 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130924 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131024 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5399612 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |